Marinomed Biotech AG Reports Positive Trial Results for Tacrolimus Eye Drops

Marinomed Biotech AG has published promising results from a phase II clinical trial on Tacrosolv eye drops. The study, featured in the "Clinical Ophthalmology" journal, demonstrates the drops' effectiveness in alleviating symptoms of allergic rhinoconjunctivitis. Tacrosolv, a low-dose aqueous formulation of Tacrolimus, is found to be both safe and efficient.

The placebo-controlled trial tested two different doses, showing significant reductions in ocular symptoms with a higher dose (0.005% Tacrolimus). Notably, nasal symptoms linked to allergies were also alleviated. This is significant as Tacrosolv uses a dose 20 times lower than existing market products.

The study involved adults with allergic conjunctivitis, revealing reduced symptoms within just 8 days. Marinomed's Marinosolv technology enhances Tacrolimus solubility, improving bioavailability and speeding up symptom relief. The findings suggest Tacrosolv as a viable treatment for inflammatory eye conditions.